CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Associate Editor

Marcus M. Reidenberg, M.D.

Editorial Board

Alvito P. Alvares, Ph.D.
Arthur J. Atkinson, Jr., M.D.
Daniel L. Azarnoff, M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Thorir D. Bjornsson, M.D.
Terrence F. Blaschke, M.D.
Paul Calabresi, M.D.
Donald B. Calne, M.D.
Edward A. Carr, Jr., M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Alvan R. Feinstein, M.D.
Vladimir Fencl, M.D.
Robert B. Forney, Ph.D.
Emil Frei III, M.D.
Milo Gibaldi, Ph.D.
Leo E. Hollister, M.D.
Leonard Horowitz, Ph.D.
Aryeh Hurwitz, M.D.
Murray E. Jarvik, M.D.
Werner Kalow, M.D.
Stanley A. Kaplan, Ph.D.
Arthur S. Keats, M.D.
Henn Kutt, M.D.
Louis Lasagna, M.D.
Paul S. Leitman, M.D., Ph.D.
Louis Lemberger, M.D., Ph.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
David T. Lowenthal, M.D.
Daniel S. Lukas, M.D.
Arno G. Motulsky, M.D.
Alan S. Nies, M.D.
Lawrence G. Raisz, M.D.
Albert Sjoerdsma, M.D., Ph.D.
Jay Tepperman, M.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.
Richard Weinshilboum, M.D.
Louis Weinstein, M.D.
Alastair J. J. Wood, M.B.Ch.B.

Volume 36, July-December 1984

The C. V. Mosby Company, St. Louis

Volume 36
Copyright © 1984 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 36

Author index

A

Adjepon-Yamoah KK: *see* Woolhouse et al, 374
Aguila E: *see* Lopez et al, 444
Alföldi S: *see* Farsang et al, 588
Alken RG, Belz GG, Haegele KD, Meinicke T, Schechter PJ: Kinetics of fenoximone, a new cardiotonic, in healthy subjects, 209
Alván G, Grind M, Graffner C, Sjöqvist F: Relationship of *N*-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism, 515
Andersen LB: *see* Boel et al, 121
Andersson P-O, H-Andersen H, Hagman A, Henning R: Potassium sparing by amiloride during thiazide therapy in hypertension, 197
Arnold MA: *see* Spindel et al, 402
Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L: Fluoxetine kinetics and protein binding in normal and impaired renal function, 138
—, Kenner CH, Sloan RS, Pottratz ST: Multiple-dose ciprofloxacin kinetics in normal subjects, 384
Asano M: *see* Nakashima et al, 436
Aslanian WS: *see* Wedlund et al, 773
Ayres EJ: *see* Hoeg et al, 555

B

von Bahr C: *see* Spina et al, 677
Bailey KR: *see* Hoeg et al, 555
Bain RP: *see* Freier et al, 737
Bakke OM: *see* Lønning et al, 796
Barnett G: *see* Chiang and Barnett, 234
—: *see* Chiang et al, 704
Barr J: *see* Maronde et al, 431
Battit GE: *see* Fahmy et al, 470
Baz R: *see* Lopez et al, 444
Beiter DJ: *see* Schachtel et al, 151
Belz GG: *see* Alken et al, 209
Benowitz NL, Jacob P III: Nicotine and carbon monoxide intake from high- and low-yield cigarettes, 265
—, Kuyt F, Jacob P III: Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking, 74
Benyunes MC: *see* Smith et al, 551
Bergstrom RF: *see* Aronoff et al, 138
Bertilsson L: *see* Woolhouse et al, 374
Bessa AM, Zanella MT, Saragoça MA, Mulinari RA, Czepielewski M, Ribeiro AB, Ramos OL: Acute hemodynamic and humoral effects of metoclopramide on blood pressure control improvement in subjects with diabetic orthostatic hypotension, 738
Bigelow GE: *see* Preston et al, 534
—: *see* Stitzer et al, 244
Birgersson C: *see* Spina et al, 677
Bjornsson TD: *see* Smith et al, 551
Blache D: *see* Renaud et al, 389
Blehaut HM: *see* Levy et al, 661
Boel J, Andersen LB, Rasmussen B, Hansen SH, Døssing M: Hepatic drug metabolism and physical fitness, 121
Bonmarchand GP: *see* Roux et al, 363
Booker WM: *see* Young et al, 811
Borges JLC, Schran HF, Evans WS, Rogol AD, Kaiser DL, MacLeod RM, Boyett RL, Elton RL, Thorner MO: Mesulergine, a new dopamine agonist: Effects on anterior pituitary function and kinetics, 696
Bou E: *see* Hoeg et al, 555
Boyett RL: *see* Borges et al, 696
Branch RA: *see* Wedlund et al, 773
Brandt JT, Miller MT, Hermiller J, Unverferth DV, Leier CV: Effect of oral amrinone on platelet function and survival, 260
Brazzell RK, Rees MMC, Khoo K-C, Szuna AJ, Sandor D, Hannigan J: Age and cibenzoline disposition, 613
Breen KJ: *see* Bury et al, 82
Breimer DD: *see* Kleinbloesem et al, 396
Brewer HB Jr: *see* Hoeg et al, 555
Brown MJ: *see* Murphy et al, 745
van Brummelen P: *see* Kleinbloesem et al, 396
Bury RW, Breen KJ, Desmond PV, Raymond K, Mashford ML: Disposition of intravenous glycofurol: Effect of hepatic cirrhosis, 82
Busto U: *see* Harrison et al, 527
Bustrack JA: *see* Johnson et al, 724

C

Carr DB: *see* Spindel et al, 402
Cayen MN: *see* Hicks et al, 493
Celotti F: *see* Pardo et al, 510
Chan L: *see* Maronde et al, 431
Chernoff S: *see* Dujovne et al, 157
Cherrier F: *see* Clozel et al, 64
Chiang C-W N, Barnett G: Marijuana effect and delta-9-tetrahydrocannabinol plasma level, 234

July, 1-150; August, 151-284; September, 285-416; October, 417-572; November, 573-710; December, 711-858.

—, Hollister LE, Kishimoto A, Barnett G: Kinetics of a naltrexone sustained-release preparation, 704
Chremos AN: *see* Sedor et al, 85
Christian CD Jr, Meredith CG, Speeg KV Jr: Cimetidine inhibits renal procainamide clearance, 221
Chung M: *see* Hilbert et al, 99
—: *see* Hilbert et al, 566
Cilmi KM: *see* Hoeldtke et al, 302
Clarke TJH: *see* Warren et al, 47
Clozel JP, Danchin N, Genton P, Thomas JL, Cherrier F: Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism, 64
Coble PA: *see* Shipley et al, 251
Coffman JD, Rasmussen HM: Effect of thromboxane synthetase inhibition in Raynaud's phenomenon, 369
Cohn JN: *see* Olivari et al, 297
Conlay L: *see* Spindel et al, 402
Connolly S, Lebsack C, Winkle RA, Harrison DC, Kates RE: Propafenone disposition kinetics in cardiac arrhythmia, 163
Cooke RG, Warsh JJ, Stancer HC, Reed KL, Persad E: The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma, 343
Cox C: *see* Sheck et al, 574
Coyle DE: *see* Hartrick et al, 546
Cremer KF, Pieper JA, Joyal M, Mehta J: Effects of diltiazem, dipyridamole, and their combination on hemostasis, 641
Cubeddu LX: *see* Halperin et al, 750
Culp JR: *see* Curry et al, 765
Curry SH, Kwon H-R, Perrin JH, Culp JR, Pepine CJ, Yu WC, Stevens JL: Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin, 765
Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M: Vancomycin disposition: The importance of age, 803
Cutler SS: *see* Weiner et al, 25
Czepielewski M: *see* Bessa et al, 738

D

Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L: Transdermal scopolamine, oral meclizine, and placebo in motion sickness, 116
Danchin N: *see* Clozel et al, 64
Dannfelt AJ: *see* Holmberg et al, 174
Davis D: *see* Schneck et al, 584
Davis HT: *see* Sheck et al, 574
Dealy RS: *see* Shipley et al, 251
DeCoursey S: *see* Dujovne et al, 157
Delhotal B: *see* Roux et al, 363
Denson DD: *see* Hartrick et al, 546
De Paolis C: *see* Pardo et al, 510
Desmond PV: *see* Bury et al, 82
Dirkes WE: *see* Hartrick et al, 546
Dollery CT: *see* Murphy et al, 745
Domino EF, Domino SE, Smith RE, Domino LE, Goulet JR, Domino KE, Zsigmond EK: Ketamine kinetics in unmedicated and diazepam-premedicated subjects, 645
Domino KE: *see* Domino et al, 645
Domino LE: *see* Domino et al, 645
Domino SE: *see* Domino et al, 645
Døssing M: *see* Boel et al, 121
Douglas MB: *see* Freier et al, 737
Dromgoole SH: *see* Narhi et al, 92
Dubuc J: *see* Hicks et al, 493
Dujovne CA, DeCoursey S, Krehbiel P, Jackson B, Chernoff S: Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol, 157
Dumont E: *see* Renaud et al, 389
Dunn MJ: *see* Sedor et al, 85
Dvornik D: *see* Hicks et al, 493
Dzindzio BS: *see* Ueda et al, 326

E

Eichler HG, Gasic S, Korn A: Effect of cianopramine, a tricyclic antidepressant, on platelet serotonin uptake and peripheral adrenergic function, 542
Eliasson K: *see* Holmberg et al, 174
Elliott HL, Jones CR, Vincent J, Lawrie CB, Reid JL: The alpha adrenoceptor antagonist properties of idazoxan in normal subjects, 190
—: *see* Pasanisi et al, 716
Elton RL: *see* Borges et al, 696
Ericsson Ö: *see* Spina et al, 677
Erill S: *see* Ruiz-Cabello and Erill, 691
Evans WS: *see* Borges et al, 696

F

Fahmy NR, Mihelakos PT, Battit GE, Lappas DG: Propranolol prevents hemodynamic and humoral events after abrupt withdrawal of nitroprusside, 470
Faiman MD, Jensen JC, Lacoursiere RB: Elimination kinetics of disulfiram in alcoholics after single and repeated doses, 520
Farine D: *see* Koren et al, 759
Farsang C, Varga K, Vajda L, Alföldi S, Kapocsi J: Effects of clonidine and guanfacine in essential hypertension, 588
Fenster PE, Hager WD, Goodman MM: Digoxin-quinidine-spironolactone interaction, 70
—: *see* Graves et al, 601
—: *see* Graves et al, 607
Fillingim JM: *see* Schachtel et al, 151
Flouvat B: *see* Roux et al, 363
Follath F: *see* Vozeh et al, 634

Freier PA, Wollam GL, Hall WD, Unger DJ, Douglas MB, Bain RP: Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension, 737

G

Galeazzi RL: *see* Platzer et al, 5
—: *see* Straehl et al, 485
Ganzinger U: *see* Rameis et al, 183
Garberg VR: *see* Olivari et al, 297
Garcia G: *see* Luderer et al, 105
Garry M: *see* Kroboth et al, 379
Gasic S: *see* Eichler et al, 542
Gengo FM, Ulatowski JA, McHugh WB: Metoprolol and alpha-hydroxymetoprolol concentrations and reduction in essential tremor, 320
Genton P: *see* Clozel et al, 64
Gibson TP, Ribner HS, Quintanilla AP: Effect of acute changes in serum digoxin concentration on renal digoxin clearance, 478
Gold R: *see* Leeder et al, 355
Goodman MM: *see* Fenster et al, 70
Gorman CA: *see* Young et al, 781
Goulet JR: *see* Domino et al, 645
Graffner C: *see* Alván et al, 515
Granit L: *see* Zylber-Katz et al, 133
Graves PE, Fenster PE, MacFarland RT, Marcus FI, Perrier D: Kinetics of digitoxin and the bis- and monodigitoxosides of digitoxigenin in normal subjects, 601
—, —, —, —, —: Kinetics of digitoxin and the bis- and monodigitoxosides of digitoxigenin in renal insufficiency, 607
Greenblatt DJ: *see* Ochs et al, 451
Gregg RE: *see* Hoeg et al, 555
Griffin SJ: *see* Shipley et al, 251
Griffith L: *see* Spindel et al, 402
Griffiths RR: *see* Preston et al, 534
Grimes AM: *see* Hoeg et al, 555
Grind M: *see* Alván et al, 515
Grochocinski VJ: *see* Shipley et al, 251
Gross KM: *see* Halperin et al, 750
Grund VR: *see* Hoogwerf et al, 217
Gural R: *see* Hilbert et al, 99
—: *see* Hilbert et al, 566
Guyot M: *see* Levy et al, 661

H

Haegele KD: *see* Alken et al, 209
Hager WD: *see* Fenster et al, 70
Hagman A: *see* Andersson et al, 197
Hall WD: *see* Freier et al, 737
Halperin AK, Gross KM, Rogers JF, Cubeddu LX: Verapamil and propranolol in essential hypertension, 750
Hamilton BP, Mersey JH, Hamilton J, Kuzbida G, Pavlis R, Levinson P: Withdrawal phenomena in subjects with essential hypertension on clonidine or tiamenidine, 628
Hamilton C: *see* Naranjo et al, 654
Hamilton J: *see* Hamilton et al, 628
Hanano M: *see* Yoshikawa et al, 201
H-Andersen H: *see* Andersson et al, 197
Hannigan J: *see* Brazzell et al, 613
Hansen SH: *see* Boel et al, 121
Harrison DC: *see* Connolly et al, 163
Harrison M, Busto U, Naranjo CA, Kaplan HL, Sellers EM: Diazepam tapering in detoxification for high-dose benzodiazepine abuse, 527
van Harten J: *see* Kleinbloesem et al, 396
Hartrick CT, Dirkes WE, Coyle DE, Raj PP, Denson DD: Influence of bupivacaine on mepivacaine protein binding, 546
Hashimoto H: *see* Nakashima et al, 436
Hay ID: *see* Young et al, 781
Heavey DJ: *see* Murphy et al, 745
Hedman A: *see* Woolhouse et al, 374
Helmers H, Van Peer A, Woestenborghs R, Noorduin H, Heykants J: Alfentanil kinetics in the elderly, 239
Henning R: *see* Andersson et al, 197
Hensen R: *see* Sheck et al, 574
Hermiller J: *see* Brandt et al, 260
Heyes J: *see* Koren et al, 759
Heykants J: *see* Helmers et al, 239
Hicks DR, Kraml M, Cayen MN, Dubuc J, Ryder S, Dvornik D: Tolrestat kinetics, 493
Hilbert JM, Chung M, Maier G, Gural R, Symchowicz S, Zampaglione N: Effect of sleep on quazepam kinetics, 99
—, —, Radwanski E, Gural R, Symchowicz S, Zampaglione N: Quazepam kinetics in the elderly, 566
Hoeg JM, Schaefer EJ, Romano CA, Bou E, Pikus AM, Zech LA, Bailey KR, Gregg RE, Wilson PWF, Sprecher DL, Grimes AM, Sebring NG, Ayres EJ, Jahn CE, Brewer HB Jr: Neomycin and plasma lipoproteins in type II hyperlipoproteinemia, 555
Hoeldtke RD, Cilmi KM, Mattis-Graves K: DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension, 302
Hollister LE: *see* Chiang et al, 704
Holmberg MF, Dannfelt AJ, Kaiser P, Rössner S, Eliasson K, Hylander B: Therapeutic and metabolic effects of sotalol, 174
Hoogwerf BJ, Grund VR, Hunninghake DB: Effect of cimetidine on plasma lipids and lipoproteins, 217
Hopkins R, Wood LE, Sinclair NM: Evaluation of methods to estimate cigarette smoke uptake, 788

Hull JH: *see* Johnson et al, 724
Humbert G: *see* Roux et al, 363
Hunninghake DB: *see* Hoogwerf et al, 217
Hussain M: *see* Silke et al, 40
Hylander B: *see* Holmberg et al, 174

I

Iga T: *see* Yoshikawa et al, 201
Inaba T, Jurima M, Nakano M, Kalow W: Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians, 670
Irvine NA: *see* Shepherd et al, 14
—: *see* Shepherd et al, 595
Isles AF: *see* Leeder et al, 355

J

Jackson B: *see* Dujovne et al, 157
Jacob P III: *see* Benowitz et al, 74
—: *see* Benowitz and Jacob, 265
Jahn CE: *see* Hoeg et al, 555
Jasinski DR: *see* Lukas et al, 127
Jensen JC: *see* Faiman et al, 520
Jiang N-S: *see* Young et al, 781
Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R: Effect of metoclopramide on digoxin absorption from tablets and capsules, 724
Johnson CL: *see* Sedor et al, 85
Johnson RE: *see* Lukas et al, 127
Jones CR: *see* Elliott et al, 190
Jones P: *see* Wallin et al, 169
Joyal M: *see* Cremer et al, 641
Juhl RP: *see* Kroboth et al, 379
—: *see* Stoehr et al, 683
Jurima M: *see* Inaba et al, 670
Jusko WJ: *see* Milsap et al, 824

K

Kaiser DL: *see* Borges et al, 696
Kaiser P: *see* Holmberg et al, 174
Kalow W: *see* Inaba et al, 670
van Kammen DP: *see* Scheinin et al, 33
Kaplan HL: *see* Harrison et al, 527
—: *see* Naranjo et al, 654
Kapocsi J: *see* Farsang et al, 588
Kates RE: *see* Connolly et al, 163
Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H: Hemodynamic effects of iloprost, a prostacyclin analog, 464
Kawamura K: *see* Kubo et al, 456
Kawasaki S: *see* Yoshikawa et al, 201
Kenner CH: *see* Aronoff et al, 384
Khoo K-C: *see* Brazzell et al, 613
Khouw V: *see* Naranjo et al, 654
Kishimoto A: *see* Chiang et al, 704
Klein MD: *see* Weiner et al, 25
Kleinbloesem CH, van Harten J, de Leede LGJ, van Brummelen P, Breimer DD: Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system, 396
Klÿn JGM: *see* Lamberts et al, 620
Koren G, Farine D, Maresky D, Taylor J, Heyes J, Soldin S, MacLeod S: Significance of the endogenous digoxin-like substance in infants and mothers, 759
Korn A: *see* Eichler et al, 542
Koshakji RP: *see* Raghuram et al, 51
Kraml M: *see* Hicks et al, 493
Krehbiel P: *see* Dujovne et al, 157
Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, Juhl RP: Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration, 379
—: *see* Stoehr et al, 683
Kubo S, Nishioka A, Nishimura H, Kawamura K, Takatsu T: Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure, 456
Kupfer DJ: *see* Shipley et al, 251
Kuyt F: *see* Benowitz et al, 74
Kuzbida G: *see* Hamilton et al, 628
Kuzma RJ: *see* Wallin et al, 169
Kvinnsland S: *see* Lønning et al, 796
Kwon H-R: *see* Curry et al, 765

L

Lacoursiere RB: *see* Faiman et al, 520
Lamberts SWJ, Klÿn JGM, Oosterom R: Mechanism of action and tolerance of mesulergine, 620
Lane AC: *see* Schachtel et al, 151
Lappas DG: *see* Fahmy et al, 470
Lasagna L: *see* Madan et al, 712
Lawrie CB: *see* Elliott et al, 190
Lebsack C: *see* Connolly et al, 163
de Leede LGJ: *see* Kleinbloesem et al, 396
Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, MacLeod SM: Ceftazidime disposition in acute and stable cystic fibrosis, 355
Leier CV: *see* Brandt et al, 260
Lemberger L: *see* Aronoff et al, 138
Leroy JA: *see* Roux et al, 363
Lesko LJ: *see* Cutler et al, 803
Levine TB: *see* Olivari et al, 297
Levinson P: *see* Hamilton et al, 628
Levy M: *see* Zylber-Katz et al, 133
Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA: Stripentol kinetics in epilepsy: Nonlinearity and interactions, 661
Liang R: *see* Madan et al, 712
Liebson IA: *see* Preston et al, 534
—: *see* Stitzer et al, 244
Lillevold PE: *see* Dahl et al, 116
Lin M-S: *see* Shepherd et al, 595
Linnoila M: *see* Scheinin et al, 33

Loiseau P: *see* Levy et al, 661
Lønning PE, Kvinnsland S, Bakke OM: Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer, 796
Lopez LM, Mehta JL, Baz R, Aguila E: Effects of nitrendipine and hydralazine on plasma catecholamines in essential hypertension, 444
Lucas SG: *see* Young et al, 811
Ludden TM: *see* Shepherd et al, 14
—: *see* Shepherd et al, 595
Luderer JR, Nicholas GG, Neumyer MM, Riley DL, Vary JE, Garcia G, Schneck DW: Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon, 105
—: *see* Schneck et al, 584
Lukas SE, Jasinski DR, Johnson RE: Electroencephalographic and behavioral correlates of buprenorphine administration, 127

M

MacFarland RT: *see* Graves et al, 601
—: *see* Graves et al, 607
Machacek D: *see* Young et al, 781
MacLeod RM: *see* Borges et al, 696
MacLeod S: *see* Koren et al, 759
—: *see* Leeder et al, 355
Madan M, Mehta G, Weintraub M, Lasagna L, Liang R: Perioperative prophylaxis with cephalosporins, 712
Magometschnigg D: *see* Rameis et al, 183
Maier G: *see* Hilbert et al, 99
Malveaux FJ: *see* Young et al, 811
Marcus FI: *see* Graves et al, 601
—: *see* Graves et al, 607
Maresky D: *see* Koren et al, 759
Maronde RF, Barr J, Vlachakis ND, Spencer CA, Chan L: Oral potassium chloride and amiloride in hydrochlorothiazide-induced potassium loss, 431
Marwaha R: *see* Johnson et al, 724
Mashford ML: *see* Bury et al, 82
Mattis-Graves K: *see* Hoeldtke et al, 302
McAllister CB: *see* Wedlund et al, 773
McCabe CH: *see* Weiner et al, 25
McCall A: *see* Spindel et al, 402
McEachran AB: *see* Shipley et al, 251
McHugh WB: *see* Gengo et al, 320
McNamara PJ: *see* Stoeckel et al, 500
McNay JL: *see* Shepherd et al, 595
McSharry DR: *see* Pasanisi et al, 716
Mehta G: *see* Madan et al, 712
Mehta J: *see* Cremer et al, 641
—: *see* Lopez et al, 444
Meinicke T: *see* Alken et al, 209
Mellström B: *see* Spina et al, 677
—: *see* Woolhouse et al, 374
Meredith CG: *see* Christian et al, 221
Meredith PA: *see* Pasanisi et al, 716
Mersey JH: *see* Hamilton et al, 628
Migliore PJ: *see* Schwartz and Migliore, 19
Mihelakos PT: *see* Fahmy et al, 470
Miller L: *see* Brandt et al, 260
Milsap RL, Plaisance KI, Jusko WJ: Prednisolone disposition in obese men, 824
Miyazaki M: *see* Nakashima et al, 436
Moirot E: *see* Roux et al, 363
Monaghan AT: *see* Warren et al, 47
Moreland TA: *see* Levy et al, 661
Morgan M: *see* Wallin et al, 169
Morris EA: *see* Young et al, 811
Mulinari RA: *see* Bessa et al, 738
Murphy MB, Brown MJ, Scriven AJI, Heavey DJ, Dollery CT: Nifedipine and alpha adrenoceptor antagonism, 745
Myers MG: Beta adrenoceptor antagonism and pressor response to phenylephrine, 57

N

Nagai K: *see* Nakano et al, 271
Nakano M: *see* Inaba et al, 670
Nakano S, Watanabe H, Nagai K, Ogawa N: Circadian stage–dependent changes in diazepam kinetics, 271
Nakashima M, Asano M, Ohguchi S, Hashimoto H, Seki T, Miyazaki M, Takenaka T: Amosulalol, a combined alpha and beta adrenoceptor antagonist: Kinetics after intravenous and oral doses, 436
Narang PK: *see* Cutler et al, 803
Naranjo CA, Sellers EM, Kaplan HL, Hamilton C, Khouw V: Acute kinetic and dynamic interactions of zimelidine with ethanol, 654
—: *see* Harrison et al, 527
Narhi D, Dromgoole SH, Rakestraw DC, Paulus HE: Tiflamizole elimination from plasma in rheumatoid arthritis, 92
Nash RM, Stein L, Penno MB, Passananti GT, Vesell ES: Sources of interindividual variations in acetaminophen and antipyrine metabolism, 417
Nelson G: *see* Silke et al, 40
Neumyer MM: *see* Luderer et al, 105
Nicholas GG: *see* Luderer et al, 105
Niederberger W: *see* Platzer et al, 5
Ninan PT: *see* Scheinin et al, 33
Ninos M: *see* Cutler et al, 803
Nishimura H: *see* Kubo et al, 456
Nishioka A: *see* Kubo et al, 456
Noorduin H: *see* Helmers et al, 239
Norris RM: *see* Paxton and Norris, 337

O

Ochs HR, Greenblatt DJ, Verburg-Ochs B: Propranolol interactions with diazepam, lorazepam, and alprazolam, 451
Offer-Ohlsen D: *see* Dahl et al, 116
Ogawa N: *see* Nakano et al, 271

Ohguchi S: *see* Nakashima et al, 436
Olivari MT, Garberg VR, Selby T, Cohn JN, Levine TB: Acute hemodynamic and hormonal response to indoramin in congestive heart failure, 297
O'Neill WM Jr: *see* Wallin et al, 169
Oosterom R: *see* Lamberts et al, 620
Otten M: *see* Vozeh et al, 634

P

Pardo A, Celotti F, De Palois C: Ceruletide analgesia in biliary colic, 510
Pasanisi F, Elliott HL, Meredith PA, McSharry DR, Reis JL: Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects, 716
Passananti GT: *see* Nash et al, 417
Paulus HE: *see* Narhi et al, 92
Pavlis R: *see* Hamilton et al, 628
Paxton JW, Norris RM: Propranolol disposition after acute myocardial infarction, 337
Penno MB: *see* Nash et al, 417
Pepine CJ: *see* Curry et al, 765
Perrier D: *see* Graves et al, 601
—: *see* Graves et al, 607
Perrin JH: *see* Curry et al, 765
Persad E: *see* Cooke et al, 343
Pessi T: *see* Kaukinen et al, 464
Phillips JP: *see* Stoehr et al, 683
Pieper JA: *see* Cremer et al, 641
Pikus AM: *see* Hoeg et al, 555
Pittman J: *see* Young et al, 811
Plaisance KI: *see* Milsap et al, 824
Platzer R, Galeazzi RL, Niederberger W, Rosenthaler J: Simultaneous modeling of bopindolol kinetics and dynamics, 5
Pottratz ST: *see* Aronoff et al, 138
—: *see* Aronoff et al, 384
Power M: *see* Cutler et al, 803
Preston KL, Griffiths RR, Stitzer ML, Bigelow GE, Liebson IA: Diazepam and methadone interactions in methadone maintenance, 534
Pritchett ELC: *see* Smith et al, 551

Q

Quintanilla AP: *see* Gibson et al, 478

R

Radwanski E: *see* Hilbert et al, 566
Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ: Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade, 51
Raj PP: *see* Hartrick et al, 546
Rakestraw DC: *see* Narhi et al, 92
Rameis H, Magometschnigg D, Ganzinger U: The diltiazem-digoxin interaction, 183
Ramos OL: *see* Bessa et al, 738
Rasmussen B: *see* Boel et al, 121
Rasmussen HM: *see* Coffman and Rasmussen, 369
Rault R: *see* Kroboth et al, 379
Raymond K: *see* Bury et al, 82
Reed KL: *see* Cooke et al, 343
Rees MMC: *see* Brazzell et al, 613
Reid JL: *see* Elliott et al, 190
—: *see* Pasanisi et al, 716
Renaud S, Blache D, Dumont E, Thevenon C, Wissendanger T: Platelet function after cigarette smoking in relation to nicotine and carbon monoxide, 389
Ribeiro AB: *see* Bessa et al, 738
Ribner HS: *see* Gibson et al, 478
Riley DL: *see* Luderer et al, 105
Rochal RE: *see* Young et al, 811
Rogers JF: *see* Halperin et al, 750
Rogol AD: *see* Borges et al, 696
Rolf C: *see* Wallin et al, 169
Romano CA: *see* Hoeg et al, 555
Rosenthaler J: *see* Platzer et al, 5
Rössner S: *see* Holmberg et al, 174
Roux AF, Moirot E, Delhotal B, Leroy JA, Bonmarchand GP, Humbert G, Flouvat B: Metronidazole kinetics in patients with acute renal failure on dialysis: A cumulative study, 363
Ruiz-Cabello F, Erill S: Abnormal serum protein binding of acidic drugs in diabetes mellitus, 691
Russo J Jr: *see* Ziemniak et al, 228
Ryan TJ: *see* Weiner et al, 25
Ryder S: *see* Hicks et al, 493

S

Saffle JR: *see* Ziemniak et al, 228
Sandor D: *see* Brazzell et al, 613
Sandvik L: *see* Dahl et al, 116
Saragoça MA: *see* Bessa et al, 738
Sawada Y: *see* Yoshikawa et al, 201
Schachtel BP, Fillingim JM, Beiter DJ, Lane AC, Schwartz LA: Rating scales for analgesics in sore throat, 151
Schaefer EJ: *see* Hoeg et al, 555
Schechter PJ: *see* Alken et al, 209
Scheinin M, van Kammen DP, Ninan PT, Linoila M: Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia, 33
Schentag JJ: *see* Ziemniak et al, 228
Schneck DW, Luderer JR, Davis D, Vary J: Effects of nadolol and propranolol on plasma lidocaine clearance, 584
—: *see* Luderer et al, 105
Schran HF: *see* Borges et al, 696
Schwartz JB, Migliore PJ: Effect of nifedipine on serum digoxin concentration and renal digoxin clearance, 19

Schwartz LA: *see* Schachtel et al, 151
Scriven AJI: *see* Murphy et al, 745
Sebring NG: *see* Hoeg et al, 555
Sedor JR, Williams SL, Chremos AN, Johnson CL, Dunn MJ: Effects of sulindac and indomethacin on renal prostaglandin synthesis, 85
Seki T: *see* Nakashima et al, 436
Selby T: *see* Olivari et al, 297
Sellers EM: *see* Harrison et al, 527
—: *see* Naranjo et al, 654
Shand DG: *see* Smith et al, 551
Sheck L, Cox C, Davis HT, Trimble AG, Wardell WM, Hensen R: Success rates in the United States drug development system, 574
Shepherd AMM, Irvine NA, Ludden TM: Effect of food on blood hydralazine levels and response in hypertension, 14
—, —, —, Lin M-S, McNay JL: Effect of oral dose size on hydralazine kinetics and vasodepressor response, 595
Shipley JE, Kupfer DJ, Dealy RS, Griffin SJ, Coble PA, McEachran AB, Grochocinski VJ: Differential effects of amitriptyline and of zimelidine on the sleep electroencephalogram of depressed patients, 251
Silke B, Nelson G, Hussain M, Verma SP, Taylor SH: Dose-response effects of cardioselective beta blockade in coronary artery disease, 40
Silver MR: *see* Kroboth et al, 379
Simon G, Snyder DK: Altered pressor responses in long-term nitrendipine treatment, 315
Sinclair NM: *see* Hopkins et al, 788
Sjöqvist F: *see* Alván et al, 515
—: *see* Spina et al, 677
—: *see* Woolhouse et al, 374
Sloan RS: *see* Aronoff et al, 138
—: *see* Aronoff et al, 384
Smith IL: *see* Ziemniak et al, 228
Smith JA Jr: *see* Vance and Smith, 350
Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett ELC: Influence of cimetidine on verapamil kinetics and dynamics, 551
Smith RB: *see* Kroboth et al, 379
—: *see* Stoehr et al, 683
Smith RE: *see* Domino et al, 645
Snyder DK: *see* Simon and Snyder, 315
Soldin S: *see* Koren et al, 759
Soliva M: *see* Straehl et al, 485
Sorkin MI: *see* Kroboth et al, 379
Speeg KV Jr: *see* Christian et al, 221
Spencer CA: *see* Maronde et al, 431
Spina E, Birgersson C, von Bahr C, Ericsson Ö, Mellström B, Steiner E, Sjöqvist F: Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes, 677
Spindel ER, Wurtman RJ, McCall A, Carr DB, Conlay L, Griffith L, Arnold MA: Neuroendocrine effects of caffeine in normal subjects, 402
Spino M: *see* Leeder et al, 355
Sprecher DL: *see* Hoeg et al, 555
Stancer HC: *see* Cooke et al, 343
Staub J-J: *see* Vozeh et al, 634
Stein L: *see* Nash et al, 417
Steiner E: *see* Spina et al, 677
Stevens JL: *see* Curry et al, 765
Stitzer ML, Bigelow GE, Liebson IA: Single-day methadone dose alteration: Detectability and symptoms, 244
—: *see* Preston et al, 534
Stoeckel K, Tuerk H, Trueb V, McNamara PJ: Single-dose ceftriaxone kinetics in liver insufficiency, 500
Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB: Effect of contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics, 683
Straehl P, Galeazzi RL, Soliva M: Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing, 485
Sugiyama Y: *see* Yoshikawa et al, 201
Symchowicz S: *see* Hilbert et al, 99
—: *see* Hilbert et al, 566
Szuna AJ: *see* Brazzell et al, 613

T

Takatsu T: *see* Kubo et al, 456
Takenaka T: *see* Nakashima et al, 436
Taylor J: *see* Koren et al, 759
Taylor SH: *see* Silke et al, 40
Tesoro AM: *see* Leeder et al, 355
Thevenon C: *see* Renaud et al, 389
Thomas JL: *see* Clozel et al, 64
Thorner MO: *see* Borges et al, 696
Tor J: *see* Levy et al, 661
Trimble AG: *see* Sheck et al, 574
Trueb V: *see* Stoeckel et al, 500
Tuerk H: *see* Stoeckel et al, 500

U

Ueda CT, Dzindzio BS, Vosik WM: Serum disopyramide concentrations and suppression of ventricular premature contractions, 326
Ulatowski JA: *see* Gengo et al, 320
Unger DJ: *see* Freier et al, 737
Unverferth DV: *see* Brandt et al, 260
Urbach DR: *see* Johnson et al, 724

V

Vajda L: *see* Farsang et al, 588
Vance MA, Smith JA Jr: Endocrine and clinical effects of leuprolide in prostatic cancer, 350
Van Peer A: *see* Helmers et al, 239

Vapaatalo H: *see* Kaukinen et al, 464
Varga K: *see* Farsang et al, 588
Vary JE: *see* Luderer et al, 105
—: *see* Schneck et al, 584
Verburg-Ochs B: *see* Ochs et al, 451
Verma SP: *see* Silke et al, 40
Vesell ES: Complex effects of diet on drug disposition, 285
—: *see* Nash et al, 417
Veterans Administration Cooperative Study Group on Antihypertensive Agents: Time course of antihypertensive effect of low-dose captopril in mild to moderate hypertension, 307
Vincent J: *see* Elliott et al, 190
Vlachakis ND: *see* Maronde et al, 431
Vosik WM: *see* Ueda et al, 326
Vozeh S, Otten M, Staub J-J, Follath F: Influence of thyroid on theophylline kinetics, 634

W

Wagner JG: Predictability of verapamil steady-state plasma levels from single-dose data explained, 1
Wallin JD, Jones P, O'Neill WM Jr, Kuzma RJ, Morgan M, Rolf C: Effects of medroxalol on renal function and the renin-angiotensin-aldosterone axis, 169
Wardell WM: *see* Sheck et al, 574
Warden GD: *see* Ziemniak et al, 228
Warren JB, Monaghan AT, Clarke TJH: Effect of penbutolol and propranolol on normal airway response to salbutamol, 47
Warsh JJ: *see* Cooke et al, 343
Watanabe H: *see* Nakano et al, 271
Watson WA: *see* Ziemniak et al, 228
Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA: Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism, 773
Weiner DA, McCabe CH, Cutler SS, Ryan TJ, Klein MD: Plasma verapamil levels and exercise performance, 25
Weintraub M: *see* Madan et al, 712
Wender DB: *see* Stoehr et al, 683
Wilkinson GR: *see* Raghuram et al, 51
—: *see* Wedlund et al, 773
Williams KM: Kinetics of misonidazole enantiomers, 817
Williams SL: *see* Sedor et al, 85
Wilson PWF: *see* Hoeg et al, 555
Winkle RA: *see* Connolly et al, 163
Wissendanger T: *see* Renaud et al, 389
Woestenborghs R: *see* Helmers et al, 239
Wolen RL: *see* Aronoff et al, 138
Wollam GL: *see* Freier et al, 737
Wood AJJ: *see* Raghuram et al, 51
Wood LE: *see* Hopkins et al, 788
Woolhouse NM, Adjepon-Yamoah KK, Melström B, Hedman A, Bertilsson L, Sjöqvist F: Nortriptylline and debrisoquine hydroxylations in Ghanaian and Swedish subjects, 374
Wurtman RJ: *see* Spindel et al, 402

Y

Yanagida M: *see* Yoshikawa et al, 201
Ylitalo P: *see* Kaukinen et al, 464
Yoshikawa T, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawasaki S, Yanagida M: Effect of late pregnancy on salicylate, diazepam, warfarin, and propranolol binding: Use of fluorescent probes, 201
Young RC Jr, Lucas SG, Morris EA, Pittman J, Rochal RE, Malveaux FJ, Booker WM: Verofylline, a methylxanthine bronchodilator, in asthma, 811
Young WF Jr, Gorman CA, Jiang N-S, Machacek D, Hay ID: L-Thyroxine contamination of pharmaceutical D-thyroxine: Probable cause of therapeutic effect, 781
Yu WC: *see* Curry et al, 765

Z

Zampaglione N: *see* Hilbert et al, 99
—: *see* Hilbert et al, 566
Zanella MT: *see* Bessa et al, 738
Zech LA: *see* Hoeg et al, 555
Ziemniak JA, Watson WA, Saffle JR, Smith IL, Russo J Jr, Warden GD, Schentag JJ: Cimetidine kinetics during resuscitation from burn shock, 228
Zsigmond EK: *see* Domino et al, 645
Zylber-Katz E, Granit L, Levy M: Relationship between caffeine concentrations in plasma and saliva, 133

Subject index

A

Abuse, high-dose benzodiazepine, diazepam tapering in detoxification for (Harrison et al), 527
Absorption, digoxin, from tablets and capsules, effect of metoclopramide on (Johnson et al), 724
Aceglutamide aluminum (USAN List No. 250), 146
Acetaminophen and antipyrine metabolism, sources of interindividual variations in (Nash et al), 417
Acid glycoprotein concentration, alpha-1, triazolam protein binding and correlation with (Kroboth et al), 379
Acidic drugs, abnormal serum protein binding of, in diabetes mellitus (Ruiz-Cabello and Erill), 691
Action and tolerance of mesulergine, mechanism of (Lamberts et al), 620
Acyclovir sodium (USAN List No. 253), 571
Adinazolam mesylate (USAN List No. 250), 147
Adrenergic function, peripheral, and platelet serotonin uptake, effect of cianopramine, tricyclic antidepressant, on (Eichler et al), 542
Adrenoceptor, alpha, antagonism and calcium channel blockade, combined, in normal subjects (Pasanisi et al), 716
nifedipine and (Murphy et al), 745
antagonist, alpha, properties of idazoxan in normal subjects (Elliott et al), 190
combined alpha and beta, amosulalol: kinetics after intravenous and oral doses (Nakashima et al), 436
beta, antagonism and pressor response to phenylephrine (Myers), 57
Age and cibenzoline disposition (Brazzell et al), 613
importance of: vancomycin disposition (Cutler et al), 803
Agonist, new dopamine, mesulergine: effects on anterior pituitary function and kinetics (Borges et al), 696
Airway response, normal, to salbutamol, effect of penbutolol and propranolol on (Warren et al), 47
Alcoholics, elimination kinetics of disulfiram in, after single and repeated doses (Faiman et al), 520
Aldosterone-renin-angiotensin axis, renal function and, effects of medroxalol on (Wallin et al), 169
Alfentanil kinetics in elderly (Helmers et al), 239
Alfuzosin hydrochloride (USAN List No. 254), 709
Alpha-1 acid glycoprotein concentration, triazolam protein binding and correlation with (Kroboth et al), 379
Alpha adrenoceptor antagonism and calcium channel blockade, combined, in normal subjects (Pasanisi et al), 716
antagonist properties of idazoxan in normal subjects (Elliott et al), 190
and beta adrenoceptor antagonist, combined, amosulalol: kinetics after intravenous and oral doses (Nakashima et al), 436
-hydroxymetoprolol and metoprolol concentrations and reduction in essential tremor (Gengo et al), 320
nifedipine and (Murphy et al), 745
Alprazolam, diazepam, and lorazepam, propranolol interactions with (Ochs et al), 451
lorazepam, triazolam, and temazepam kinetics, effect of oral contraceptives on (Stoehr et al), 683
Altanserin tartrate (USAN List No. 251), 280
American Society for Clinical Pharmacology and Therapeutics
Notes 278, 408, 570, 832
Abstract form 149, 283
Future meeting dates and sites, 18, 156
Amiflamine and its metabolite, *N*-demethylation of, relationship of, to debrisoquine hydroxylation polymorphism (Alván et al), 515
Amifloxacin (USAN List No. 250), 146
Amiloride and potassium chloride, oral, in hydrochlorothiazide-induced potassium loss (Maronde et al), 431
potassium sparing by, during thiazide therapy in hypertension (Andersson et al), 197
Aminoglutethimide, effect of, on antipyrine, theophylline, and digitoxin disposition in breast cancer (Lønning et al), 796
Amitriptyline and zimelidine, differential effects of, on sleep electroencephalogram of depressed patients (Shipley et al), 251
Amosulalol, combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses (Nakashima et al), 436

July, 1-150, August, 151-284; September, 285-416; October, 417-572; November, 573-710; December, 711-858.

Amrinone, oral, effect of, on platelet function and survival (Brandt et al), 260
Analgesia, ceruletide, in biliary colic (Pardo et al), 510
Analgesics, rating scales for, in sore throat (Schachtel et al), 151
Analog, prostacyclin, iloprost, hemodynamic effects of (Kaukinen et al), 464
Angiotensin-aldosterone-renin axis, renal function and, effects of medroxalol on (Wallin et al), 169
Antagonism, alpha adrenoceptor, and calcium channel blockade, combined, in normal subjects (Pasanisi et al), 716
alpha adrenoceptor, nifedipine and (Murphy et al), 745
beta adrenoceptor, and pressor response to phenylephrine (Myers), 57
Antagonist, alpha adrenoceptor, properties of idazoxan in normal subjects (Elliott et al), 190
combined alpha and beta adrenoceptor, amosulalol: kinetics after intravenous and oral doses (Nakashima et al), 436
Antidepressant, tricyclic, cianopramine, effect of, on platelet serotonin uptake and peripheral adrenergic function (Eichler et al), 542
Antihypertensive effect of low-dose captopril, time course of, in mild to moderate hypertension (VA Cooperative Study Group), 307
Antipyrine and acetaminophen metabolism, sources of interindividual variations in (Nash et al), 417
theophylline, and digitoxin disposition in breast cancer, effect of aminoglutethimide on (Lønning et al), 796
Arclofenin (USAN List No. 251), 280
Arrhythmia, cardiac, propafenone disposition kinetics in (Connolly et al), 163
Arthritis, rheumatoid, tiflamizole elimination from plasma in (Narhi et al), 92
Asthma, verofylline, methylxanthine bronchodilator, in (Young et al), 811
Azelastine hydrochloride (USAN List No. 254), 710

B

Behavioral correlates, electroencephalographic and, of buprenorphine administration (Lukas et al), 127
Benzodiazepine abuse, high-dose, diazepam tapering in detoxification for (Harrison et al), 527
Beta adrenoceptor antagonism and pressor response to phenylephrine (Myers), 57
and alpha adrenoceptor antagonist, combined, amosulalol: kinetics after intravenous and oral doses (Nakashima et al), 436
Beta adrenoceptor—cont'd
blockade, cardioselective, dose-response effects of, in coronary artery disease (Silke et al), 40
polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not (Raghuram et al), 51
Biclodil hydrochloride (USAN List No. 254), 709
Biliary colic, ceruletide analgesia in (Pardo et al), 510
Binding, abnormal serum protein, of acidic drugs in diabetes mellitus (Ruiz-Cabello and Erill), 691
mepivacaine protein, influence of bupivacaine on (Hartrick et al), 546
protein, fluoxetine kinetics and, in normal and impaired renal function (Aronoff et al), 138
salicylate, diazepam, warfarin, and propranolol, effect of late pregnancy on: use of fluorescent probes (Yoshikawa et al), 201
triazolam protein, and correlation with alpha-1 acid glycoprotein concentration (Kroboth et al), 379
Bis- and monodigitoxosides of digitoxigenin and digitoxin, kinetics of, in normal subjects (Graves et al), 601
in renal insufficiency (Graves et al), 607
Blacks with hypertension, blood pressure, plasma volume, and catecholamine levels during enalapril therapy in (Freier et al), 731
Blockade, beta, polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not (Raghuram et al), 51
calcium channel, combined alpha adrenoceptor antagonism and, in normal subjects (Pasanisi et al), 716
cardioselective beta, dose-response effects of, in coronary artery disease (Silke et al), 40
Blood pressure control improvement, acute hemodynamic and humoral effects of metoclopramide on, in subjects with diabetic orthostatic hypotension (Bessa et al), 738
heart rate and, effects of propranolol and verapamil on, in hyperthyroidism (Clozel et al), 64
plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension (Freier et al), 731
Books received, 416
Bopindolol kinetics and dynamics, simultaneous modeling of (Platzer et al), 5
Bronchodilator, methylxanthine, verofylline, in asthma (Young et al), 811
Bupivacaine, influence of, on mepivacaine protein binding (Hartrick et al), 546

Buprenorphine administration, electroencephalographic and behavioral correlates of (Lukas et al), 127
Burn shock, resuscitation from, cimetidine kinetics during (Ziemniak et al), 228

C

Caffeine concentrations in plasma and saliva, relationship between (Zylber-Katz et al), 133
neuroendocrine effects of, in normal subjects (Spindel et al), 402
Calcium channel blockade, combined alpha adrenoceptor antagonism and, in normal subjects (Pasanisi et al), 716
Canadian Caucasians, mephenytoin and sparteine pharmacogenetics in (Inaba et al), 670
Cancer, breast, antipyrine, theophylline, and digitoxin disposition in, effect of aminoglutethimide on (Lønning et al), 796
prostatic, leuprolide in, endocrine and clinical effects of (Vance and Smith), 350
Captopril, effects of, on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure (Kubo et al), 456
low-dose, time course of antihypertensive effect of, in mild to moderate hypertension (VA Cooperative Study Group), 307
Carbon monoxide and nicotine, cigarette smoking in relation to, platelet function after (Renaud et al), 389
intake from high- and low-yield cigarettes (Benowitz and Jacob), 265
Cardiac arrhythmia, propafenone disposition kinetics in (Connolly et al), 163
Cardiotonic, new, fenoximone, kinetics of, in healthy subjects (Alken et al), 209
Cardiovascular and hormal effects of cigarette smoking, influence of nicotine on (Benowitz et al), 74
Catecholamine(s) levels, blood pressure, and plasma volume during enalapril therapy in blacks with hypertension (Freier et al), 731
plasma, in essential hypertension, effects of nitrendipine and hydralazine on (Lopez et al), 444
Caucasians, Canadian, mephenytoin and sparteine pharmacogenetics in (Inaba et al), 670
mephenytoin hydroxylation deficiency in: frequency of new oxidative drug metabolism polymorphism (Wedlund et al), 773
Cefbuperazone (USAN List No. 251), 282
Cefpimizole (USAN List No. 250), 147
sodium (USAN List No. 251), 282
Ceftazidime disposition in acute and stable cystic fibrosis (Leeder et al), 355
Ceftriaxone kinetics, single-dose, in liver insufficiency (Stoeckel et al), 500
Cephalosporins, perioperative prophylaxis with (Madan et al), 712
Cerebrospinal fluid of patients with chronic schizophrenia, effect of propranolol on monoamine metabolites in (Scheinin et al), 33
Ceruletide analgesia in biliary colic (Pardo et al), 510
Channel, calcium, blockade, combined alpha adrenoceptor antagonism and, in normal subjects (Pasanisi et al), 716
Cianopramine, tricyclic antidepressant, effect of, on platelet serotonin uptake and peripheral adrenergic function (Eichler et al), 542
Cibenzoline disposition and age (Brazzell et al), 613
Cicloprolol hydrochloride (USAN List No. 255), 834
Cigarette(s), high- and low-yield, nicotine and carbon monoxide intake from (Benowitz and Jacob), 265
smoke uptake, evaluation of methods to estimate (Hopkins et al), 788
smoking, cardiovascular and hormonal effects of, influence of nicotine on (Benowitz et al), 74
platelet function after, in relation to nicotine and carbon monoxide (Renaud et al), 389
Ciladopa hydrochloride (USAN List No. 251), 280
Cimetidine, effect of, on plasma lipids and lipoproteins (Hoogwerf et al), 217
influence of, on verapamil kinetics and dynamics (Smith et al), 551
inhibits renal procainamide clearance (Christian et al), 221
kinetics during resuscitation from burn shock (Ziemniak et al), 228
Ciprofloxacin kinetics, multiple-dose, in normal subjects (Aronoff et al), 384
Ciramadol hydrochloride (USAN List No. 252), 413
Circadian stage–dependent changes in diazepam kinetics (Nakano et al), 271
Cirrhosis, hepatic, effect of: disposition of intravenous glycofurol (Bury et al), 82
Clearance, plasma lidocaine, effects of nadolol and propranolol on (Schneck et al), 584
renal digoxin, effect of acute changes in serum digoxin concentration on (Gibson et al), 478
serum digoxin concentration and, effect of nifedipine on (Schwartz and Migliore), 19
procainamide, cimetidine inhibits (Christian et al), 221
Clonidine and guanfacine, effects of, in essential hypertension (Farsang et al), 588
or tiamenidine, subjects with essential hypertension on, withdrawal phenomena in (Hamilton et al), 628

Cloticasone propionate (USAN List No. 255), 835
Colic, biliary, ceruletide analgesia in (Pardo et al), 510
Concentrations, caffeine, in plasma and saliva, relationship between (Zylber-Katz et al), 133
serum digoxin, and renal digoxin clearance, effect of nifedipine on (Schwartz and Migliore), 19
effect of acute changes in, on renal digoxin clearance (Gibson et al), 478
Contamination, L-thyroxine, of pharmaceutical D-thyroxine: probable cause of therapeutic effect (Young et al), 781
Contraceptives, oral, effect of, on triazolam, temazepam, alprazolam, and lorazepam kinetics (Stoehr et al), 683
Contractions, ventricular premature, suppression of, serum disopyramide concentrations and (Ueda et al), 326
Coronary artery disease, cardioselective beta blockade in, dose-response effects of (Silke et al), 40
Coumermycin sodium (USAN List No. 254), 710
Cystic fibrosis, acute and stable, ceftazidime disposition in (Leeder et al), 355

D

Dazmegrel (USAN List No. 251), 282
Dazoxiben, thromboxane synthetase inhibitor, in Raynaud's phenomenon (Luderer et al), 105
Debrisoquine and desmethylimipramine, phenotypic consistency in hydroxylation of, in healthy subjects and human liver microsomes (Spina et al), 677
nortriptyline hydroxylations in Ghanaian and Swedish subjects (Woolhouse et al), 374
hydroxylation polymorphism, relationship of *N*-demethylation of amiflamine and its metabolite to (Alván et al), 515
Delta-9-tetrahydrocannabinol plasma level, marijuana effect and (Chiang and Barnett), 234
N-Demethylation of amiflamine and its metabolite, relationship of, to debrisoquine hydroxylation polymorphism (Alván et al), 515
Depressed patients, sleep electroencephalogram of, differential effects of amitriptyline and zimelidine on (Shipley et al), 251
Desipramine and 2-hydroxydesipramine in plasma, nonlinear kinetics of (Cooke et al), 343
Desmethylimipramine and debrisoquine, phenotypic consistency in hydroxylation of, in healthy subjects and human liver microsomes (Spina et al), 677
Detoxification for high-dose benzodiazepine abuse, diazepam tapering in (Harrison et al), 527
Diabetes mellitus, acidic drugs in, abnormal serum protein binding of (Ruiz-Cabello and Erill), 691
Diabetic orthostatic hypotension, subjects with, acute hemodynamic and humoral effects of metoclopramide on blood pressure control improvement in (Bessa et al), 738
Dialysis, patients with acute renal failure on, metronidazole kinetics in: cumulative study (Roux et al), 363
Diazepam and methadone interactions in methadone maintenance (Preston et al), 534
kinetics, circadian stage–dependent changes in (Nakano et al), 271
lorazepam, and alprazolam, propranolol interactions with (Ochs et al), 451
premedicated and unmedicated subjects, ketamine kinetics in (Domino et al), 645
tapering in detoxification for high-dose benzodiazepine abuse (Harrison et al), 527
warfarin, propranolol, and salicylate binding, effect of late pregnancy on: use of fluorescent probes (Yoshikawa et al), 201
Diet, complex effects of, on drug disposition (Vesell), 285
Digitoxin and bis- and monodigitoxosides of digitoxigenin, kinetics of, in normal subjects (Graves et al), 601
in renal insufficiency (Graves et al), 607
antipyrine, and theophylline disposition in breast cancer, effect of aminoglutethimide on (Lønning et al), 796
Digitoxigenin, bis- and monodigitoxosides of, and digitoxin, kinetics of, in normal subjects (Graves et al), 601
in renal insufficiency (Graves et al), 607
Digoxin absorption from tablets and capsules, effect of metoclopramide on (Johnson et al), 724
concentration, serum, and renal digoxin clearance, effect of nifedipine on (Schwartz and Migliore), 19
effect of acute changes in, on renal digoxin clearance (Gibson et al), 478
-diltiazem interaction (Rameis et al), 183
-like substance, endogenous, significance of, in infants and mothers (Koren et al), 759
-quinidine-spironolactone interaction (Fenster et al), 70
Dihydroxyphenylserine, DL-threo-3,4-, does not exert pressor effect in orthostatic hypotension (Hoeldtke et al), 302
Diltiazem-digoxin interaction (Rameis et al), 183
dipyridamole, and their combination, effects of, on hemostasis (Cremer et al), 641
Dipyridamole, diltiazem, and their combination, effects of, on hemostasis (Cremer et al), 641

Disease, coronary artery, cardioselective beta blockade in, dose-response effects of (Silke et al), 40
Disopyramide concentrations, serum, and suppression of ventricular premature contractions (Ueda et al), 326
Disposition, drug, complex effects of diet on (Vesell), 285
Disulfiram, elimination kinetics of, in alcoholics after single and repeated doses (Faiman et al), 520
Dopamine agonist, new, mesulergine: effects on anterior pituitary function and kinetics (Borges et al), 696
Dose(s) alteration, single-day methadone; detectability and symptoms (Stitzer et al), 244
high-, benzodiazepine abuse, diazepam tapering in detoxification for (Harrison et al), 527
intravenous and oral, kinetics after: amosulalol, combined alpha and beta adrenoceptor antagonist (Nakashima et al), 436
low-, captopril, time course of antihypertensive effect of, in mild to moderate hypertension (VA Cooperative Study Group), 307
multiple-, ciprofloxacin kinetics in normal subjects (Aronoff et al), 384
-response effects of cardioselective beta blockade in coronary artery disease (Silke et al), 40
single-, ceftriaxone kinetics in liver insufficiency (Stoeckel et al), 500
data explained, predictability of verapamil steady-state plasma levels from (Wagner), 1
single and repeated, elimination kinetics of disulfiram in alcoholics after (Faiman et al), 520
size, oral, effect of, on hydralazine kinetics and vasodepressor response (Shepherd et al), 595
Dosing, intravenous and oral, isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after (Straehl et al), 485

E

Editor, note from, 573, 711
Edoxudine (USAN List No. 250), 146
Elderly, alfentanil kinetics in (Helmers et al), 239
quazepam kinetics in (Hilbert et al), 566
Electroencephalogram, sleep, of depressed patients, differential effects of amitriptyline and zimelidine on (Shipley et al), 251
Electroencephalographic and behavioral correlates of buprenorphine administration (Lukas et al), 127
Elimination kinetics of disulfiram in alcoholics after single and repeated doses (Faiman et al), 520
Elimination—cont'd
tiflamizole, from plasma in rheumatoid arthritis (Narhi et al), 92
Enalapril therapy, blood pressure, plasma volume and catecholamine levels during, in blacks with hypertension (Freier et al), 731
Enantiomers, misonidazole, kinetics of (Williams), 817
Endocrine and clinical effects of leuprolide in prostatic cancer (Vance and Smith), 350
Epilepsy, stiripentol kinetics in: nonlinearity and interactions (Levy et al), 661
Epirubicin hydrochloride (USAN List No. 252), 415
Epostane (USAN List No. 251), 282
Errata to Graves et al, 723
Ethanol with zimelidine, acute kinetic and dynamic interactions of (Naranjo et al), 654
Exercise performance, plasma verapamil levels and (Weiner et al), 25

F

Fenoximone, new cardiotonic, kinetics of, in healthy subjects (Alken et al), 209
Fenretidine (USAN List No. 255), 835
Fentiazac (USAN List No. 250), 147
Fluorescent probes, use of: effect of late pregnancy on salicylate, diazepam, warfarin, and propranolol binding (Yoshikawa et al), 201
Fluorometholone acetate (USAN List No. 252), 413
Fluoxetine kinetics and protein binding in normal and impaired renal function (Aronoff et al), 138
Flupirtine maleate (USAN List No. 253), 572
Food, effect of, on blood hydralazine levels and response in hypertension (Shepherd et al), 14
Fumoxicillin (USAN List No. 255), 836
Function and survival, platelet, effect of oral amrinone on (Brandt et al), 260
anterior pituitary, and kinetics, effects on: mesulergine, new dopamine agonist (Borges et al), 696
peripheral adrenergic, and platelet serotonin uptake, effect of cianopramine, tricyclic antidepressant, on (Eichler et al), 542
platelet, after cigarette smoking in relation to nicotine and carbon monoxide (Renaud et al), 389
renal, humoral factors, and arterial and venous pressure, effects of captopril on, in severe chronic congestive heart failure (Kubo et al), 456
thyroid, influence of, on theophylline kinetics (Vozeh et al), 634

G

Ghanaian and Swedish subjects, nortriptyline and debrisoquine hydroxylations in (Woolhouse et al), 374

Glycofurol, intravenous, disposition of: effect of hepatic cirrhosis (Bury et al), 82
Glycoprotein concentration, alpha-1 acid, triazolam protein binding and correlation with (Kroboth et al), 379
Guanfacine and clonidine, effects of, in essential hypertension (Farsang et al), 588

H

Heart failure, congestive, acute hemodynamic and hormonal response to indoramin in (Olivari et al), 297
severe chronic congestive, arterial and venous pressure, renal function, and humoral factors in, effects of captopril on (Kubo et al), 456
rate and blood pressure, effects of propranolol and verapamil on, in hyperthyroidism (Clozel et al), 64
Hemodynamic and hormonal response, acute, to indoramin in congestive heart failure (Olivari et al), 297
humoral effects, acute, of metoclopramide on blood pressure control improvement in subjects with diabetic orthostatic hypotension (Bessa et al), 738
events after abrupt withdrawal of nitroprusside, propranolol prevents (Fahmy et al), 470
effects of iloprost, prostacyclin analog (Kaukinen et al), 464
plasma nitroglycerin concentrations and, of sublingual, ointment, and controlled-release forms of nitroglycerin (Curry et al), 765
Hemostasis, effects of diltiazem, dipyridamole, and their combination on (Cremer et al), 641
Hepatic cirrhosis, effect of: disposition of intravenous glycofurol (Bury et al), 82
drug metabolism and physical fitness (Boel et al), 121
Hormonal and hemodynamic response, acute, to indoramin in congestive heart failure (Olivari et al), 297
effects, cardiovascular and, of cigarette smoking, influence of nicotine on (Benowitz et al), 74
Humoral and hemodynamic events after abrupt withdrawal of nitroprusside, propranolol prevents (Fahmy et al), 470
effects, hemodynamic and, acute, of metoclopramide on blood pressure control improvement in subjects with diabetic orthostatic hypotension (Bessa et al), 738
factors, arterial and venous pressure, and renal function, effects of captopril on, in severe chronic congestive heart failure (Kubo et al), 456
Hydralazine and nitrendipine, effects of, on plasma catecholamines in essential hypertension (Lopez et al), 444
kinetics and vasodepressor response, effect of oral dose size on (Shepherd et al), 595
levels, blood, and response in hypertension, effect of food on (Shepherd et al), 14
Hydrochlorothiazide-induced potassium loss, oral potassium chloride and amiloride in (Maronde et al), 431
2-Hydroxydesipramine and desipramine in plasma, nonlinear kinetics of (Cooke et al), 343
Hydroxylation(s) deficiency, mephenytoin, in Caucasians: frequency of new oxidative drug metabolism polymorphism (Wedlund et al), 773
of desmethylimipramine and debrisoquine, phenotypic consistency in, in healthy subjects and human liver microsomes (Spina et al), 677
nortriptyline and debrisoquine, in Ghanaian and Swedish subjects (Woolhouse et al), 374
polymorphism, debrisoquine, relationship of *N*-demethylation of amiflamine and its metabolite to (Alván et al), 515
4-Hydroxypropranolol levels but not beta blockade, polymorphic ability to metabolize propranolol alters (Raghuram et al), 51
Hyperlipidemics, normo- and, serum lipids in, after methyldopa and propranolol (Dujovne et al), 157
Hyperlipoproteinemia, type II, neomycin and plasma lipoproteins in (Hoeg et al), 555
Hypertension, blood hydralazine levels and response in, effect of food on (Shepherd et al), 14
pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with (Freier et al), 731
essential, effects of clonidine and guanfacine in (Farsang et al), 588
nitrendipine and hydralazine on plasma catecholamines in (Lopez et al), 444
subjects with, on clonidine or tiamenidine, withdrawal phenomena in (Hamilton et al), 628
verapamil and propranolol in (Halperin et al), 750
mild to moderate, low-dose captopril in, time course of antihypertensive effect of (VA Cooperative Study Group), 307
thiazide therapy in, potassium sparing by amiloride during (Andersson et al), 197
Hyperthyroidism, heart rate and blood pressure in, effects of propranolol and verapamil on (Clozel et al), 64

Hypotension, diabetic orthostatic, subjects with, acute hemodynamic and humoral effects of metoclopramide on blood pressure control in (Bessa et al), 738
orthostatic, pressor effect in, DL-threo-3,4-dihydroxyphenylserine does not exert (Hoeldtke et al), 302

I

Idazoxan, alpha adrenoceptor antagonist properties of, in normal subjects (Elliott et al), 190
Iloprost, prostacyclin analog, hemodynamic effects of (Kaukinen et al), 464
Imiloxan hydrochloride (USAN List No. 253), 572
Indium In 111 oxyquinoline (USAN List No. 250), 148
Indomethacin, sulindac and, effects of, on renal prostaglandin synthesis (Sedor et al), 85
Indoramin, acute hemodynamic and hormonal response to, in congestive heart failure (Olivari et al), 297
hydrochloride (USAN List No. 253), 571
Infants and mothers, significance of endogenous digoxin-like substance in (Koren et al), 759
Infarction, acute myocardial, propranolol disposition after (Paxton and Norris), 337
Infusion, rectal, to steady state with osmotic system, nifedipine kinetics and dynamics during (Kleinbloesem et al), 396
Inhibition, thromboxane synthetase, effect of, in Raynaud's phenomenon (Coffman and Rasmussen), 369
Inhibitor, thromboxane synthetase, dazoxiben, in Raynaud's phenomenon (Luderer et al), 105
Insufficiency, liver, single-dose ceftriaxone kinetics in (Stoeckel et al), 500
renal, kinetics of digitoxin and bis- and monodigitoxosides of digitoxigenin in (Graves et al), 607
Interaction(s), acute kinetic and dynamic, of zimeldine with ethanol (Naranjo et al), 654
and nonlinearity: stiripentol kinetics in epilepsy (Levy et al), 661
diazepam and methadone, in methadone maintenance (Preston et al), 534
digoxin-quinidine-spironolactone (Fenster et al), 70
diltiazem-digoxin (Rameis et al), 183
propranolol, with diazepam, lorazepam, and alprazolam (Ochs et al), 451
Iofetamine HCl I 123 (USAN List No. 254), 709
Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing (Straehl et al), 485
Itraconazole (USAN List No. 252), 415

K

Ketamine kinetics in unmedicated and diazepam-premedicated subjects (Domino et al), 645
Ketorolac tromethamine (USAN List No. 250), 147

L

Leuprolide, endocrine and clinical effects of, in prostatic cancer (Vance and Smith), 350
Lidocaine clearance, plasma, effects of nadolol and propranolol on (Schneck et al), 584
Lipids and lipoproteins, plasma, effect of cimetidine on (Hoogwerf et al), 217
serum, in normo- and hyperlipidemics after methyldopa and propranolol (Dujovne et al), 157
Lipoproteins, lipids and, plasma, effect of cimetidine on (Hoogwerf et al), 217
plasma, and neomycin, in type II hyperlipoproteinemia (Hoeg et al), 555
Liver insufficiency, single-dose ceftriaxone kinetics in (Stoeckel et al), 500
microsomes, human, and healthy subjects, phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in (Spina et al), 677
Lorazepam, alprazolam, and diazepam, propranolol interactions with (Ochs et al), 451
triazolam, temazepam, and alprazolam kinetics, effect of oral contraceptives on (Stoehr et al), 683
Losulazine hydrochloride (USAN List No. 252), 414
Lutrelin acetate (USAN List No. 251), 279

M

Marijuana effect and delta-9-tetrahydrocannabinol plasma level (Chiang and Barnett), 234
Mecetronium ethylsulfate (USAN List No. 253), 572
Meclizine, oral, transdermal scopolamine, and placebo, in motion sickness (Dahl et al), 116
Medroxalol, effects of, on renal function and renin-angiotensin-aldosterone axis (Wallin et al), 169
Mefloquine hydrochloride (USAN List No. 251), 281
Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians (Inaba et al), 670
hydroxylation deficiency in Caucasians: frequency of new oxidative drug metabolism polymorphism (Wedlund et al), 773
Mepivacaine protein binding, influence of bupivacaine on (Hartrick et al), 546

Meptazinol hydrochloride (USAN List No. 250), 146
Mesulergine, mechanism of action and tolerance of (Lamberts et al), 620
new dopamine agonist: effects on anterior pituitary function and kinetics (Borges et al), 696
Metabolic effects, therapeutic and, of sotalol (Holmberg et al), 174
Metabolism, acetaminophen and antipyrine, sources of interindividual variations in (Nash et al), 417
hepatic drug, and physical fitness (Boel et al), 121
polymorphism, new oxidative drug, frequency of: mephenytoin hydroxylation deficiency in Caucasians (Wedlund et al), 773
Metabolite(s), amiflamine and its, *N*-demethylation of, relationship of, to debrisoquine hydroxylation polymorphism (Alván et al), 515
monoamine, in cerebrospinal fluid of patients with chronic schizophrenia, effect of propranolol on (Scheinin et al), 33
Methadone and diazepam interactions in methadone maintenance (Preston et al), 534
dose alteration, single-day: detectability and symptoms (Stitzer et al), 244
Methyldopa and propranolol, serum lipids in normo- and hyperlipidemics after (Dujovne et al), 157
Methylxanthine bronchodilator, verofylline, in asthma (Young et al), 811
Metoclopramide, acute hemodynamic and humoral effects of, on blood pressure control improvement in subjects with diabetic orthostatic hypotension (Bessa et al), 738
effect of, on digoxin absorption from tablets and capsules (Johnson et al), 724
Metoprolol and alpha-hydroxymetoprolol concentrations and reduction in essential tremor (Gengo et al), 320
Metronidazole kinetics in patients with acute renal failure on dialysis: cumulative study (Roux et al), 363
Microsomes, human liver, and healthy subjects, phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in (Spina et al), 677
Misonidazole enantiomers, kinetics of (Williams), 817
Modeling, simultaneous, of bopindolol kinetics and dynamics (Platzer et al), 5
Mono- and bisdigitoxosides of digitoxigenin and digitoxin, kinetics of, in normal subjects (Graves et al), 601
in renal insufficiency (Graves et al), 607
Monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia, effect of propranolol on (Scheinin et al), 33
Mothers and infants, significance of endogenous digoxin-like substance in (Koren et al), 759
Motion sickness, transdermal scopolamine, oral meclizine, and placebo in (Dahl et al), 116
Myocardial infarction, acute, propranolol disposition after (Paxton and Norris), 337

N

Nadolol and propranolol, effects of, on plasma lidocaine clearance (Schneck et al), 584
Nafarelin acetate (USAN List No. 251), 279
Naltrexone sustained-release preparation, kinetics of (Chiang et al), 704
Neomycin and plasma lipoproteins in type II hyperlipoproteinemia (Hoeg et al), 555
Neuroendocrine effects of caffeine in normal subjects (Spindel et al), 402
Nicotine and carbon monoxide, cigarette smoking in relation to, platelet function after (Renaud et al), 389
intake from high- and low-yield cigarettes (Benowitz and Jacob), 265
influence of, on cardiovascular and hormonal effects of cigarette smoking (Benowitz et al), 74
Nifedipine and alpha adrenoceptor antagonism (Murphy et al), 745
effect of, on serum digoxin concentration and renal digoxin clearance (Schwartz and Migliore), 19
kinetics and dynamics during rectal infusion to steady state with osmotic system (Kleinbloesem et al), 396
Nitrendipine and hydralazine, effects of, on plasma catecholamines in essential hypertension (Lopez et al), 444
treatment, long-term, altered pressor responses in (Simon and Snyder), 315
Nitroglycerin concentrations, plasma, and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin (Curry et al), 765
Nitroprusside, abrupt withdrawal of, hemodynamic and humoral events after, propranolol prevents (Fahmy et al), 470
Normo- and hyperlipidemics, serum lipids in, after methyldopa and propranolol (Dujovne et al), 157
Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects (Woolhouse et al), 374

O

Obese men, prednisolone disposition in (Milsap et al), 824
Octenidine saccharin (USAN List No. 251), 281
Ofloxacin (USAN List No. 252), 413

Ofornine (USAN List No. 255), 834
Orthostatic hypotension, diabetic, subjects with, acute hemodynamic and humoral effects of metoclopramide on blood pressure control in (Bessa et al), 738
pressor effect in, DL-threo-3,4-dihydroxyphenylserine does not exert (Hoeldtke et al), 302
Osmotic system, rectal infusion to steady state with, nifedipine kinetics and dynamics during (Kleinbloesem et al), 396

P

Penbutolol and propranolol, effect of, on normal airway response to salbutamol (Warren et al), 47
Pharmacogenetics, mephenytoin and sparteine, in Canadian Caucasians (Inaba et al), 670
Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes (Spina et al), 677
Phenylephrine, beta adrenoceptor antagonism and pressor response to (Myers), 57
Physical fitness, hepatic drug metabolism and (Boel et al), 121
Pinadoline (USAN List No. 250), 145
Piquindone hydrochloride (USAN List No. 252), 414
Piriprost (USAN List No. 253), 571
potassium (USAN List No. 252), 414
Piroxicam olamine (USAN List No. 251), 280
Pituitary function and kinetics, anterior, effects on: mesulergine, new dopamine agonist (Borges et al), 696
Plasma and saliva, caffeine concentrations in, relationship between (Zylber-Katz et al), 133
desipramine and 2-hydroxydesipramine in, nonlinear kinetics of (Cooke et al), 343
tiflamizole elimination from, in rheumatoid arthritis (Narhi et al), 92
volume, catecholamine levels, and blood pressure during enalapril therapy in blacks with hypertension (Freier et al), 731
Platelet function after cigarette smoking in relation to nicotine and carbon monoxide (Renaud et al), 389
and survival, effect of oral amrinone on (Brandt et al), 260
serotonin uptake and peripheral adrenergic function, effect of cianopramine, tricyclic antidepressant, on (Eichler et al), 542
Plicamycin (USAN List No. 250), 148
Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade (Raghuram et al), 51
Polymorphism, debrisoquine hydroxylation, relationship of *N*-demethylation of amiflamine and its metabolite to (Alván et al), 515
Polymorphism—cont'd
new oxidative drug metabolism, frequency of: mephenytoin hydroxylation deficiency in Caucasians (Wedlund et al), 773
Potassium chloride and amiloride, oral, in hydrochlorothiazide-induced potassium loss (Maronde et al), 431
loss, hydrochlorothiazide-induced, oral potassium chloride and amiloride in (Maronde et al), 431
sparing by amiloride during thiazide therapy in hypertension (Andersson et al), 197
Prednisolone disposition in obese men (Milsap et al), 824
Pregnancy, late, effect of, on salicylate, diazepam, warfarin, and propranolol binding: use of fluorescent probes (Yoshikawa et al), 201
Preparation, naltrexone sustained-release, kinetics of (Chiang et al), 704
Pressor effect, DL-threo-3,4-dihydroxyphenylserine does not exert, in orthostatic hypotension (Hoeldtke et al), 302
responses, altered, in long-term nitrendipine treatment (Simon and Snyder), 315
to phenylephrine, beta adrenoceptor antagonism and (Myers), 57
Pressure, arterial and venous, renal function, and humoral factors, effects of captopril on, in severe chronic congestive heart failure (Kubo et al), 456
Probes, fluorescent, use of: effect of late pregnancy on salicylate, diazepam, warfarin, and propranolol binding (Yoshikawa et al), 201
Procainamide clearance, renal, cimetidine inhibits (Christian et al), 221
Progabide (USAN List No. 252), 414
Propafenone disposition kinetics in cardiac arrhythmia (Connolly et al), 163
Prophylaxis, perioperative, with cephalosporins (Madan et al), 712
Propranolol and nadolol, effects of, on plasma lidocaine clearance (Schneck et al), 584
verapamil, effects of, on heart rate and blood pressure in hyperthyroidism (Clozel et al), 64
disposition after acute myocardial infarction (Paxton and Norris), 337
effect of, on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia (Scheinin et al), 33
interactions with diazepam, lorazepam, and alprazolam (Ochs et al), 451
methyldopa and, serum lipids in normo- and hyperlipidemics after (Dujovne et al), 157
penbutolol and, effect of, on normal airway response to salbutamol (Warren et al), 47

Propranolol—cont'd
polymorphic ability to metabolize, alters 4-hydroxypropranolol levels but not beta blockade (Raghuram et al), 51
prevents hemodynamic and humoral events after abrupt withdrawal of nitroprusside (Fahmy et al), 470
salicylate, diazepam, and warfarin binding, effect of late pregnancy on: use of fluorescent probes (Yoshikawa et al), 201
verapamil and, in essential hypertension (Halperin et al), 750
Prostacyclin analog, iloprost, hemodynamic effects of (Kaukinen et al), 464
Prostaglandin synthesis, renal, effects of sulindac and indomethacin on (Sedor et al), 85
Prostatic cancer, leuprolide in, endocrine and clinical effects of (Vance and Smith), 350
Protein binding, abnormal serum, of acidic drugs in diabetes mellitus (Ruiz-Cabello and Erill), 691
fluoxetine kinetics and, in normal and impaired renal function (Aronoff et al), 138
mepivacaine, influence of bupivacaine on (Hartrick et al), 546
triazolam, and correlation with alpha-1 acid glycoprotein concentration (Kroboth et al), 379

Q

Quazepam kinetics, effect of sleep on (Hilbert et al), 99
in elderly (Hilbert et al), 566
Quinidine-spironolactone-digoxin interaction (Fenster et al), 70
Quinpirole hydrochloride (USAN List No. 255), 835

R

Rates, success, in United States drug development system (Sheck et al), 574
Rating scales for analgesics in sore throat (Schachtel et al), 151
Raynaud's phenomenon, dazoxiben, thromboxane synthetase inhibitor in (Luderer et al), 105
effect of thromboxane synthetase inhibition in (Coffman and Rasmussen), 369
Rectal infusion to steady state with osmotic system, nifedipine kinetics and dynamics during (Kleinbloesem et al), 396
Renal digoxin clearance, effect of acute changes in serum digoxin concentration on (Gibson et al), 478
serum digoxin concentration and, effect of nifedipine on (Schwartz and Migliore), 19
failure, acute, patients with, on dialysis, metronidazole kinetics in: cumulative study (Roux et al), 363
Renal—cont'd
function and renin-angiotensin-aldosterone axis, effects of medroxalol on (Wallin et al), 169
humoral factors, and arterial and venous pressure, effects of captopril on, in severe chronic congestive heart failure (Kubo et al), 456
normal and impaired, fluoxetine kinetics and protein binding in (Aronoff et al), 138
insufficiency, kinetics of digitoxin and bis- and monodigitoxosides of digitoxigenin in (Graves et al), 607
procainamide clearance, cimetidine inhibits (Christian et al), 221
prostaglandin synthesis, effects of sulindac and indomethacin on (Sedor et al), 85
Renin-angiotensin-aldosterone axis, renal function and, effects of medroxalol on (Wallin et al), 169
Resuscitation from burn shock, cimetidine kinetics during (Ziemniak et al), 228
Rheumatoid arthritis, tiflamizole elimination from plasma in (Narhi et al), 92
Ristianol phosphate (USAN List No. 251), 281

S

Salbutamol, normal airway response to, effect of penbutolol and propranolol on (Warren et al), 47
Salicylate, diazepam, warfarin, and propranolol binding, effect of late pregnancy on: use of fluorescent probes (Yoshikawa et al), 201
Saliva, plasma and, caffeine concentrations in, relationship between (Zylber-Katz et al), 133
Schizophrenia, chronic, effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with (Scheinin et al), 33
Scopolamine, transdermal, oral meclizine, and placebo in motion sickness (Dahl et al), 116
Serotonin uptake, platelet, and peripheral adrenergic function, effect of cianopramine, tricyclic antidepressant, on (Eichler et al), 542
Shock, burn, resuscitation from, cimetidine kinetics during (Ziemniak et al), 228
Sleep, effect of, on quazepam kinetics (Hilbert et al), 99
electroencephalogram of depressed patients, differential effects of amitriptyline and zimelidine on (Shipley et al), 251
Smoke uptake, cigarette, evaluation of methods to estimate (Hopkins et al), 788
Smoking, cigarette, cardiovascular and hormonal effects of, influence of nicotine on (Benowitz et al), 74

Smoking—cont'd
platelet function after, in relation to nicotine and carbon monoxide (Renaud et al), 389
Somatrem (USAN List No. 255), 836
Sotalol, therapeutic and metabolic effects of (Holmberg et al), 174
Sparing, potassium, by amiloride during thiazide therapy in hypertension (Andersson et al), 197
Sparteine and mephenytoin pharmacogenetics in Canadian Caucasians (Inaba et al), 670
Spironolactone-digoxin-quinidine interaction (Fenster et al), 70
Steady-state plasma levels, verapamil, predictability of, from single-dose data explained (Wagner), 1
rectal infusion to, with osmotic system, nifedipine kinetics and dynamics during (Kleinbloesem et al), 396
Stiripentol kinetics in epilepsy: nonlinearity and interactions (Levy et al), 661
Sufentanil citrate (USAN List No. 255), 834
Sulindac and indomethacin, effects of, on renal prostaglandin synthesis (Sedor et al), 85
Suppression of ventricular premature contractions, serum disopyramide concentrations and (Ueda et al), 326
Suproclone (USAN List No. 255), 835
Survival and function, platelet, effect of oral amrinone on (Brandt et al), 260
Swedish and Ghanaian subjects, nortriptyline and debrisoquine hydroxylations in (Woolhouse et al), 374
Synthesis, renal prostaglandin, effects of sulindac and indomethacin on (Sedor et al), 85
Synthetase inhibition, thromboxane, effect of, in Raynaud's phenomenon (Coffman and Rasmussen), 369
inhibitor, thromboxane, dazoxiben, in Raynaud's phenomenon (Luderer et al), 105
System, United States drug development, success rates in (Sheck et al), 574

T

Temazepam, alprazolam, lorazepam, and triazolam kinetics, effect of oral contraceptives on (Stoehr et al), 683
Theophylline, digitoxin, and antipyrine disposition in breast cancer, effect of aminoglutethimide on (Lønning et al), 796
kinetics, influence of thyroid function on (Vozeh et al), 634
Thiazide therapy in hypertension, potassium sparing by amiloride during (Andersson et al), 197
Throat, sore, rating scales for analgesics in (Schachtel et al), 151
Thromboxane synthetase inhibition, effect of, in Raynaud's phenomenon (Coffman and Rasmussen), 369
inhibitor, dazoxiben, in Raynaud's phenomenon (Luderer et al), 105
Thyroid function, influence of, on theophylline kinetics (Vozeh et al), 634
Thyroxine, L-, contamination of pharmaceutical D-thyroxine: Probable cause of therapeutic effect (Young et al), 781
D-, pharmaceutical, L-thyroxine contamination of: probable cause of therapeutic effect (Young et al), 781
Tiacrilast (USAN List No. 254), 710
Tiamenidine or clonidine, subjects with essential hypertension on, withdrawal phenomena in (Hamilton et al), 628
Tiapamil hydrochloride (USAN List No. 251), 279
Tiflamizole elimination from plasma in rheumatoid arthritis (Narhi et al), 92
Tolerance and action of mesulergine, mechanism of (Lamberts et al), 620
Tolrestat (USAN List No. 250), 145
kinetics (Hicks et al), 493
Tremor, essential, reduction in, metoprolol and alpha-hydroxymetoprolol concentrations and (Gengo et al), 320
Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration (Kroboth et al), 379
temazepam, alprazolam, and lorazepam kinetics, effect of oral contraceptives on (Stoehr et al), 683
Trientine hydrochloride (USAN List No. 251), 281
Type II hyperlipoproteinemia, neomycin and plasma lipoproteins in (Hoeg et al), 555

U

United States drug development system, success rates in (Sheck et al), 574

V

Vancomycin disposition: importance of age (Cutler et al), 803
Vasodepressor response and hydralazine kinetics, effect of oral dose size on (Shepherd et al), 595
Ventricular premature contractions, suppression of, serum disopyramide concentrations and (Ueda et al), 326
Verapamil and propranolol in essential hypertension (Halperin et al), 750
kinetics and dynamics, influence of cimetidine on (Smith et al), 551
levels, plasma, and exercise performance (Weiner et al), 25

Verapamil—cont'd
propranolol and, effects of, on heart rate and blood pressure in hyperthyroidism (Clozel et al), 64
steady-state plasma levels, predictability of, from single-dose data explained (Wagner), 1
Verofylline, methylxanthine bronchodilator, in asthma (Young et al), 811

W

Warfarin, propranolol, salicylate, and diazepam binding, effect of late pregnancy on: use of fluorescent probes (Yoshikawa et al), 201
Withdrawal, abrupt, of nitroprusside, propranolol prevents hemodynamic and humoral events after (Fahmy et al), 470
phenomena in subjects with essential hypertension on clonidine or tiamenidine (Hamilton et al), 628

Z

Zimelidine and amitriptyline, differential effects of, on sleep electroencephalogram of depressed patients (Shipley et al), 251
with ethanol, acute kinetic and dynamic interactions of (Naranjo et al), 654
Zofenopril calcium (USAN List No. 250), 145